Form 4: Recursion Pharma Director Sells Shares Under 10b5-1 Plan

Recursion Pharmaceuticals Director Christopher Gibson executed a planned sale of 40,000 Class A Common Stock shares at $3.25, following a conversion from Class B shares.

Summary

• Christopher Gibson, a Director of Recursion Pharmaceuticals, Inc. (RXRX), reported transactions on March 23, 2026.
• The transactions involved the conversion of 40,000 shares of Class B Common Stock into Class A Common Stock.
• Immediately following the conversion, 40,000 shares of Class A Common Stock were sold at a price of $3.25 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Gibson on May 12, 2025.
• Following these transactions, Mr. Gibson directly holds 906,556 shares of Class A Common Stock and 4,483,334 shares of Class B Common Stock.
• Mr. Gibson also has indirect beneficial ownership of Class B Common Stock through LAHWRAN-3 LLC (386,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (50,000 shares).
• Mr. Gibson holds several stock options to buy Class A Common Stock with various exercise prices and vesting schedules, including options at $7.25, $10.09, $8.55, $11.40, and $2.48.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sale was pre-planned under a Rule 10b5-1 plan, mitigating concerns typically associated with insider selling.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, rather than reactive, sale.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence, though this is mitigated by the pre-planned nature.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are generally viewed as less impactful than open market sales, as they are pre-scheduled and often part of personal financial planning rather than a reaction to new, material non-public information. However, the sale price of $3.25 per share for Class A Common Stock is a data point for market participants.

Related Party Transactions

• Christopher Gibson has indirect beneficial ownership of Class B Common Stock through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, entities where he holds management or trustee roles.

Stakeholder Impact

• Shareholders: Minor impact. A director's sale, even if planned, can sometimes lead to slight negative sentiment, but the 10b5-1 plan mitigates this. The volume of shares sold (40,000) is relatively small compared to the total outstanding shares and Mr. Gibson's remaining holdings.

Key Dates

Recommendation

The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically does not signal a change in the company's fundamental outlook or warrant a strong buy/sell recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Recursion Pharmaceuticals, RXRX, Christopher Gibson, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Class A Common Stock, Class B Common Stock, Stock Options